0a46e0e2_Text_View___ClinicalTrials_gov__Assigned_Interventions
[Arms] Experimental: 5 Participants in this group will receive a cyclical regimen of teriparatide. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an option to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5. [Assigned Interventions] 
Drug: Teriparatide Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically. Dietary Supplement: Calcium Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg. Dietary Supplement: Vitamin D3 Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
Cyclic Versus Daily Teriparatide on Bone Mass - Full Text View - ClinicalTrials.gov